ALK Abello nominates Gitte Aabo and Dr. Bertil Lindmark for upcoming election to its Board as Independent Directors

– DENMARK, Hoersholm –  ALK Abello (CPH: ALK-B) today announced the nomination of Gitte Aabo, CEO of GN Hearing A/S, and Dr. Bertil Lindmark, MD, Chief Medical Officer of Galecto A/S for the upcoming election to its Board of Directors as new independent directors.

If their nominations are approved, the number of shareholder-elected members on ALK’s Board will increase from five to seven, with the majority of the Board members independent, in line with Denmark’s Recommendations on Corporate Governance.

“These nominations expand and strengthen ALK’s Board, and I have no doubt that Gitte Aabo and Bertil Lindmark’s experience in the life science sector, as well as their business credentials, will prove valuable assets for the company. With the three-year transformation of the company almost complete, ALK stands on the threshold of an important new stage in its development – one of sustained growth, profitability and leveraging the strong platform to pursue new initiatives.” said Board Chairman, Anders Hedegaard.

About Gitte Aabo

Gitte Aabo, a Danish citizen born in 1967, is CEO at GN Hearing, the global leader in hearing aid innovation. Before this, she was President & CEO of LEO Pharma and brings with her extensive global leadership experience and a deep understanding of international management, finance, IT, sales, and marketing, as well as considerable insights into building digital communities.

Gitte Aabo has an MSc in Business administration from Copenhagen Business School.

About Bertil Lindmark

Bertil Lindmark, a Swedish citizen born in 1955, is a member of the Board of Management at the clinical-stage biotechnology company, Galecto, where he is Chief Medical Officer. He will bring to ALK considerable experience across the R&D spectrum, gained over three decades in roles at AstraZeneca, Almirall, ASLAN Pharmaceuticals, and eTheRNA Immunotherapies.

Bertil Lindmark is an MD and holds a Ph.D. in Molecular Epidemiology from the University of Lund, Sweden, as well as specialist qualifications in Internal Medicine and Gastroenterology.

About ALK

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,400 people worldwide and is listed on Nasdaq Copenhagen.

For more information: https://www.alk.net/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team